AI assistant
Q/C TECHNOLOGIES, INC. — Director's Dealing 2021
Apr 21, 2021
35313_dirs_2021-04-20_93a5efd2-fd2d-49c4-a516-2f6d1e1eee1a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MyMD Pharmaceuticals, Inc. (MYMD)
CIK: 0001321834
Period of Report: 2021-04-16
Reporting Person: Rivard Paul (EVP of Operations, GC)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-04-16 | Stock Option (Right to Buy) | $2.5913 | A | 77180 | Acquired | 2023-04-16 | Common Stock (77180) | Direct |
| 2021-04-16 | Stock Option (Right to Buy) | $2.5913 | A | 77180 | Acquired | 2023-04-16 | Common Stock (77180) | Indirect |
Footnotes
F1: Received in exchange for a stock option to acquire 200,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") at $1.00 per share in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share.
F2: These options are fully vested and exercisable.
F3: Received in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share in connection with the Merger.
F4: These shares are jointly held by the reporting person and Jennifer Rivard as trustees for the Paul Rivard and Jennifer Rivard Revocable Living Trust.